We came across a bullish thesis on Alcon Inc. (ALC) on Substack by Kontra Investment Xchange. In this article, we will summarize the bulls’ thesis on ALC. Alcon Inc. (ALC)’s share was trading at 88.85 as of Nov 29th. ALC’s trailing and forward P/E were 37.97 and 25.97 respectively according to Yahoo Finance.
A doctor wearing gloves and a mask holding a pair of contact lenses in their hand.
Alcon, a global leader in eyecare, operates through its Surgical and Vision Care segments, which together position the company as a dominant force in ophthalmology. The Surgical segment, contributing 57% of sales, includes intra-ocular lenses, consumables, and advanced surgical equipment like lasers, solidifying Alcon as the top global player in surgical eyecare. Vision Care, accounting for 43% of sales, focuses on contact lenses and over-the-counter ocular health products, making Alcon the second-largest player in this segment worldwide. Based in Geneva, Switzerland, the company is well-positioned in ophthalmology markets projected to grow at a mid-single-digit rate, offering a stable foundation for long-term expansion.
Since its 2018 spin-off from Novartis, Alcon has strategically increased investments, which are now yielding results with an impressive pipeline of new products. Upcoming launches such as Vinity contact lenses in China by Q3 2024, the Unity vitreoretinal cataract system in Q4 2024, and Precision7 soft contact lenses in Q1 2025 are set to bolster market share and enhance operating margins. Additionally, introducing the Belkin Vision glaucoma laser device and AR-15512 dry eye drug in 2025 underscores Alcon’s commitment to innovation across both segments.
Despite inherent risks like potential product pipeline setbacks, regulatory challenges, competition, and financial exposures to currency fluctuations or interest rate changes, Alcon remains resilient. The company’s leading market positions and low financial gearing provide a strong defensive edge and stability in navigating uncertainties.
Alcon’s robust product lineup and foothold in growing markets signal significant potential for long-term value creation. Its ability to capitalize on secular trends in ophthalmology and execute on its growth strategy positions the company as an attractive opportunity for investors seeking exposure to a global leader with a promising outlook.
Alcon Inc. (ALC) is not on our list of the 31 Most Popular Stocks Among Hedge Funds. As per our database, 33 hedge fund portfolios held ALC at the end of the third quarter which was 22 in the previous quarter. While we acknowledge the risk and potential of ALC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than ALC but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None. This article was originally published at Insider Monkey.